OCL
Asset Logo

Objective Corporation Limited

🇦🇺 ASX

Compare
Add to watchlist
👑 Overview

📈 Performance

💰 Dividends

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual growth

💰

0.72%
Annual dividend yield

Based on the most recent dividend

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

6
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Objective Corp. Ltd. engages in the supply of information technology software and services. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2000-08-17. The Company’s Objective Content Solutions products enable customers to manage information and process governance across the enterprise. The company also enables customers to collaborate with external organizations with the security, information governance and auditability demanded by the government. Its Objective Keystone products improve efficiency and deliver government in the process of authoring, reviewing, engaging with and publishing documents. Its Objective RegWorks and Objective Reach products are focused on the delivery of government regulation technology solutions. Its Objective Planning Solutions include Objective Trapeze products, which digitally transform development application plan reviews and assessments, and Objective Alpha and Master Business Systems, which provide end-to-end building consenting solutions.

📈 Performance

Price History

+6380.70%

1M

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💰 Dividends

Payouts

💰 Annual Dividend Yield*

0.72%

💰 Annual Dividend Earnings Per $1,000 invested**

$7.19

💰 Most Recent Dividend Franked Percentage Estimate

0.00%

💰 Average Dividend Franked Percentage Estimate

97.92 %

💰 Dividend reinvestment

Learn more

* Based on the most recent dividend

** Calculated by multiplying the most recent dividend yield by $1,000

Dividend History

1Y

5Y

10Y

Graph

Table

Year
Yearly Dividend Earnings Per Share
Franking Estimate

2024

$0.00

0.00%

2023

$0.00

0.00%

2022

$0.11

0.00%

2021

$0.09

Infinity%

2020

$0.07

Infinity%

2019

$0.05

Infinity%

2018

$0.05

Infinity%

2017

$0.04

Infinity%

2016

$0.04

Infinity%

2015

$0.04

100.00%

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

0%
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$13.83

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in OCL

6

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in OCL

488 days
OCL investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50%

50k - 100k

33%

Less than 50k

17%
👶 Age of investors

18 - 25

17%

26 - 34

17%

35 - 90

67%
🙋 Legal gender of investors

Female

17%

Male

83%

Pearlers who invest in OCL also invest in...

CSL Limited

CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 30,000 full-time employees. The Company’s areas of focus and exploration include rare and serious diseases, influenza vaccines, plasma collection, and therapies for iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus segment manufactures, markets, and distributes primarily influenza-related products and provides pandemic services to governments. The Company’s CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency, dialysis and nephrology and rare diseases. The Company’s geographical areas of operation include Australia, the United States of America, Germany, the United Kingdom, Switzerland, and China. CSL’s products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.

📊 Share price

$308.11 AUD

NULL HEALTH

Find Out More

Xero Ltd. engages in the provision of online business solutions for small businesses and their advisors. The firm offers a cloud-based accounting software. Its segments include Australia and New Zealand (ANZ) and International. The firm provides online business solutions for small businesses and their advisors. The features and tools of its software platform include accepting payments, bank reconciliation, pay bills, claim expenses, bank connections, tracking projects, GST returns, payroll, contact management, data capture, online file storage, reporting, inventory, multi-currency accounting, purchase orders, quotes, accounting dashboard and managing fixed assets. The company is focused on small business operational and financial needs across area beyond accounting and compliance, such as expenses, inventory management, financial services and employee services. The firm serves various industries, such as retail, high tech, non-profit, hospitality, startups and construction.

📊 Share price

$110.04 AUD

NULL TECH

Macquarie Group Ltd. operates as a non-operating holding company. The company is headquartered in Sydney, New South Wales and currently employs 20,509 full-time employees. The company went IPO on 2007-11-05. The firm operates in asset management, retail and business banking, wealth management, leasing and asset financing, market access, commodity trading, renewables development, specialist advice, access to capital and principal investment. Its segments include Macquarie Asset Management (MAM), Banking and Financial Services (BFS), Commodities and Global Markets (CGM) and Macquarie Capital. The MAM segment provides investment solutions to clients across a range of capabilities in private markets and public investments. The BFS segment provides a range of personal banking, wealth management, and business banking products and services to retail clients, advisers, brokers, and business clients. The CGM segment is a global business offering capital and financing, risk management, market access, physical execution, and logistics solutions. Macquarie Capital segment offers advisory and capital raising services.

📊 Share price

$176.60 AUD

BHP Group Ltd. engages in the exploration, development, production and processing of iron ore, metallurgical coal and copper. The company is headquartered in Melbourne, Victoria and currently employs 37,908 full-time employees. The firm is a producer of commodities, including iron ore, copper, nickel, potash and metallurgical (steelmaking) coal. The company is focused on offering a range of resources, which provides copper for renewable energy; nickel for electric vehicles; potash for sustainable farming, and iron ore and metallurgical coal for the steel needed for global infrastructure and the energy transition. Its segments include Copper, Iron Ore, and Coal. Its Copper segment is engaged in mining of copper, silver, zinc, molybdenum, uranium, and gold. Its Iron Ore segment is engaged in mining of iron ore. Its Coal segment is engaged in mining of metallurgical coal and energy coal. The firm is also focused on operating Olympic Dam, Prominent Hill, and Carrapateena underground copper-gold mines in South Australia. The firm's operations are situated in Australia, Europe, China, Japan, India, South Korea, rest of Asia, North America and South America.

📊 Share price

$43.41 AUD

NULL RESOURCES

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

📊 Share price

$90.18 AUD

NULL AUSTRALIA

NULL BETA

Want more shares? Try these...

Oceana Lithium Ltd. operates as a mineral exploration and development company. The company is headquartered in Perth, Western Australia. The company went IPO on 2022-07-01. The firm is focused on the discovery and delineation of lithium mineral resources in two mining-friendly jurisdictions, the state of Ceara, Brazil, and the Northern Territory, Australia. The firm's projects include Solonopole Lithium Project and the Napperby Lithium project. The Solonopole lithium project, located in Ceara State, northeastern Brazil, consists of approximately eight mining permits covering approximately 114 square kilometers (Km2). The Napperby lithium project consists of a granted exploration license (EL32836) covering an area of approximately 650km2 and an exploration license application (ELA32841) covering an area of more than 512km2. The Napperby lithium project is located within the Northern Arunta pegmatite province near the settlement of Ti Tree, approximately 250km northwest of Alice Springs and 250km south of Tennant Creek.

📊 Share price

$0.30 AUD

Octava Minerals Ltd. operates as a mineral exploration and development company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-09-16. The firm is engaged in acquiring interests in a portfolio of mineral exploration properties within Western Australia with the main focus being on lithium, gold, platinum group metals (PGMs), and nickel sulphide prospects. Its projects include East Pilbara (Talga), East Kimberley (Panton North and Copernicus North), and Yallalong. The East Pilbara (Talga) project comprises eight granted exploration licenses prospective for lithium and gold, located approximately 30 kilometers (km) to the north of the Marble Bar town site. The East Kimberley project comprises two tenements, the Panton North project (E80/5455) and the Copernicus North project (E80/5459) located in the Halls Creek Orogen. The Yallalong project is located in the northwestern portion of the Murchison region approximately 220km to the northeast of the port of Geraldton and covers an area of about 65.5km2.

📊 Share price

$0.14 AUD

Oceania Healthcare Ltd. engages in the provision of health care solution. The firm operates through three segments. The care segment is engaged in providing products, such as traditional care beds and care suites. The segment is involved in the provision of accommodation, care and related services to the Company’s aged care residents; and services, such as meals and care packages to independent living residents. The village operations segment is engaged in providing products, such as independent living and rental properties. The segment is involved in the provision of accommodation and related services to independent residents in the Company’s retirement villages. The other segment is involved in the provision of support services to the Company, which includes administration, marketing and operations. In addition, this segment includes the provision of training by the Wesley Institute of Learning.

📊 Share price

$0.74 AUD

Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. The company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

📊 Share price

$0.37 AUD
Compare
Add to watchlist